This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| UK Science and Technology Committee | |
|---|---|
| Name | Science and Technology Committee |
| Chamber | House of Commons |
| Legislature | Parliament of the United Kingdom |
| Established | 1966 |
| Jurisdiction | United Kingdom |
| Chair | Speaker (selected) |
| Parent committee | Select Committees |
UK Science and Technology Committee
The Science and Technology Committee is a select committee of the House of Commons that scrutinises research, innovation and related public policy, interacting with institutions such as Department for Science, Innovation and Technology, Royal Society, Wellcome Trust, European Research Council, and agencies like UK Research and Innovation, National Physical Laboratory, Met Office, and CERN. It examines spending, regulation and strategy across programmes delivered by bodies including Medical Research Council, Biotechnology and Biological Sciences Research Council, Engineering and Physical Sciences Research Council, Science Museum, and universities such as University of Oxford, University of Cambridge, and Imperial College London.
The committee originated from earlier Commons select committees informed by inquiries into post‑war science policy, interacting with landmark reports like the Robbins Report, the Fleming Report, and the work of figures such as Lord Rutherford, Sir Isaac Newton, and Frederick Sanger. Reconstituted across successive Parliaments, it has operated during administrations of Harold Wilson, Margaret Thatcher, Tony Blair, and Theresa May, and has responded to crises associated with incidents like the Chernobyl disaster, the Bovine spongiform encephalopathy crisis, and the COVID-19 pandemic. The committee’s evolution paralleled institutional changes involving Research Excellence Framework, Higher Education Funding Council for England, and initiatives from the European Commission.
The committee’s remit covers oversight of expenditure and policy delivered by executive entities including Department for Business, Energy and Industrial Strategy, Department for Digital, Culture, Media and Sport, and delivery partners such as Public Health England, National Institute for Health and Care Research, and UK Space Agency. Responsibilities include scrutinising white papers, legislation like the Human Fertilisation and Embryology Act 1990, regulatory frameworks tied to Genetically Modified Organisms Directive, and international agreements involving Horizon 2020 and European Atomic Energy Community. It summons witnesses from organisations including Academy of Medical Sciences, Royal Academy of Engineering, British Antarctic Survey, and private firms such as GlaxoSmithKline, AstraZeneca, and Rolls-Royce.
Membership comprises MPs nominated by party groups and appointed by the House of Commons Commission, with chairs elected under rules influenced by the Parliamentary Voting System and Constituencies Act 2011 and precedent from select committees like Public Accounts Committee and Foreign Affairs Committee. Members have included parliamentarians associated with constituencies such as Cambridge (UK Parliament constituency), Oxford West and Abingdon, and roles overlapping with peers from the House of Lords Science and Technology Select Committee. The committee draws expert evidence from fellows of the Royal Society, professors at University College London, researchers at Francis Crick Institute, and directors of institutions like the Natural History Museum.
Proceedings typically involve oral evidence sessions held in committee rooms of the Palace of Westminster, publication of written evidence, and production of reports debated in Westminster Hall and subject to Government responses within specified timeframes under Standing Orders derived from practice with committees such as Treasury Committee and Home Affairs Committee. Inquiries have examined topics including research funding models, antimicrobial resistance alongside organisations like the World Health Organization, net zero technologies involving Committee on Climate Change, data governance intersecting with Information Commissioner's Office, and pandemic preparedness with witnesses from Public Health Wales and NHS England.
Reports have influenced policy changes in areas spanning clinical trials regulation with implications for Medicines and Healthcare products Regulatory Agency, research integrity reforms linked to the Concordat to Support Research Integrity, and investment strategies coordinated with UK Industrial Strategy and programmes supported by British Business Bank. Findings have informed legislation amendments in Parliament, procurement practices at Defence Science and Technology Laboratory, and strategic partnerships with international bodies like Organisation for Economic Co-operation and Development and G7 science initiatives. The committee’s recommendations have been cited by universities, charities such as Cancer Research UK, and industry consortia including TechUK.
Critics have contended that the committee’s influence can be constrained by partisan dynamics involving parties such as the Conservative Party (UK), Labour Party (UK), and Scottish National Party, by ministerial non‑compliance exemplified in notable exchanges with ministers from Department of Health and Social Care, and by tensions over security redactions related to projects with GCHQ and Ministry of Defence. Controversies have arisen around high‑profile inquiries where witnesses from companies like Theranos (company) would have been relevant, debates over funding allocations affecting institutions such as Queen Mary University of London, and disputes about access to classified material similar to issues encountered by committees overseeing Intelligence and Security Committee of Parliament.
Category:Select Committees of the British House of Commons